Ann: Generics Sales Update, page-7

Interesting that IDT's market cap is still less than $40m considering the potential sales of Temozolomide alone ...

The original (Temodar) had sales, before the parent exipired in 2013, of over $800M !
http://www.fiercepharma.com/special-report/temodar

The initial stock quantities manufactured for Mayne had been expected to satisfy demand until mid-2017 but uptake has been better than anticipated, demanding earlier than expected replenishment - for the higher dose strengths of 180mg and 250mg.

So that's only Temozolomide.
There is also a minimum of 6 further products "that should attain marketable status this calendar year".  

Kinda surprising that the s/p is less than 20c